Peter E. Schwartz

16.7k total citations · 1 hit paper
258 papers, 10.3k citations indexed

About

Peter E. Schwartz is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Peter E. Schwartz has authored 258 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 89 papers in Reproductive Medicine and 50 papers in Molecular Biology. Recurrent topics in Peter E. Schwartz's work include Ovarian cancer diagnosis and treatment (87 papers), Endometrial and Cervical Cancer Treatments (36 papers) and HER2/EGFR in Cancer Research (33 papers). Peter E. Schwartz is often cited by papers focused on Ovarian cancer diagnosis and treatment (87 papers), Endometrial and Cervical Cancer Treatments (36 papers) and HER2/EGFR in Cancer Research (33 papers). Peter E. Schwartz collaborates with scholars based in United States, Italy and Australia. Peter E. Schwartz's co-authors include Thomas Rutherford, Joseph T. Chambers, Alessandro D. Santin, Ernest I. Kohorn, Gil Mor, Stefania Bellone, Masoud Azodi, Dan‐Arin Silasi, Elena Ratner and Emiliano Cocco and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Peter E. Schwartz

255 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography

1979 418 citations Peter E. Schwartz et al. profile →

Peers

Countries citing papers authored by Peter E. Schwartz

Since Specialization

Citations

This map shows the geographic impact of Peter E. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Schwartz more than expected).

Fields of papers citing papers by Peter E. Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter E. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Schwartz. The network helps show where Peter E. Schwartz may publish in the future.

Co-authorship network of co-authors of Peter E. Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of Peter E. Schwartz. A scholar is included among the top collaborators of Peter E. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter E. Schwartz. Peter E. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors affecting continuous participation in follow‐up evaluations during a lifestyle intervention programme for type 2 diabetes prevention: The Feel4Diabetes‐study 2024 ·Diabetic Medicine ·(unknown), Konstantinos Makrilakis, George Dafoulas, Violeta Iotova, Κaloyan Tsochev, Rumyana Dimova, Greet Cardon, Esther M. González‐Gil, Luís A. Moreno, Jemina Kivelä, Jaana Lindström, Imre Rurik, (unknown), Patrick Timpel, Peter E. Schwartz, Christina Mavrogianni, Yannis Μanios, Stavros Liatis, (unknown)	1
2	Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer 2023 ·Cancer Medicine ·Brenda Cartmel, Fangyong Li, Yang Zhou, (unknown), Lingeng Lu, Reed Mszar, Maura Harrigan, Jennifer A. Ligibel, Radhika Gogoi, Peter E. Schwartz, Harvey A. Risch, Melinda L. Irwin	6
3	Effect of exercise on body composition among women with ovarian cancer 2022 ·Journal of Cancer Survivorship ·Anlan Cao, Brenda Cartmel, Fangyong Li, (unknown), Maura Harrigan, Jennifer A. Ligibel, Radhika Gogoi, Peter E. Schwartz, Melinda L. Irwin, Leah M. Ferrucci	8
4	Financial toxicity in patients with gynecologic malignancies: a cross sectional study 2021 ·Journal of Gynecologic Oncology ·Burak Zeybek, Emily Webster, (unknown), Joan Tymon‐Rosario, Alan Balch, Gary Altwerger, Mitchell Clark, Gulden Menderes, Gloria S. Huang, Masoud Azodi, Elena Ratner, Peter E. Schwartz, Alessandro D. Santin, Vaagn Andikyan	14
5	Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma 2020 ·Gynecologic Oncology Reports ·(unknown), Natália Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin	6
6	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement 2018 ·Clinical Cancer Research ·Stefania Bellone, Natália Buza, Jungmin Choi, Luca Zammataro, Laurie M. Gay, Julia A. Elvin, David L. Rimm, Yuting Liu, Elena Ratner, Peter E. Schwartz, Alessandro D. Santin	35
7	Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer 2018 ·Journal of Cancer Research and Clinical Oncology ·Gary Altwerger, Esther Borges Florsheim, Gulden Menderes, Jonathan Black, Carlton L. Schwab, Gregory M. Gressel, (unknown), (unknown), (unknown), Gloria S. Huang, Babak Litkouhi, Masoud Azodi, Dan-Arin Silasi, Alessandro D. Santin, Peter E. Schwartz, Elena Ratner	20
8	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo 2017 ·Medical Oncology ·Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan D. Black, Salvatore Lopez, Francesca Pettinella, Alice Masserdotti, Luca Zammataro, Babak Litkouhi, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin	15
9	The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report. 2015 ·PubMed Central ·(unknown), A. Bale, (unknown), (unknown), Hari A. Deshpande, (unknown), Peter E. Schwartz, Erin Hofstatter	7
10	Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo 2015 ·Gynecologic Oncology ·Carlton L. Schwab, Diana P. English, Jonathan Black, Stefania Bellone, Salvatore Lopez, Emiliano Cocco, Elena Bonazzoli, Beatrice Bussi, Federica Predolini, Francesca Ferrari, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Thomas Rutherford, Peter E. Schwartz, Alessandro D. Santin	26
11	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo 2015 ·Molecular Cancer Therapeutics ·Salvatore Lopez, Emiliano Cocco, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L. Schwab, Diana P. English, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Peter E. Schwartz, Corrado Terranova, Roberto Angioli, Alessandro D. Santin	26
12	Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo 2014 ·Gynecologic Oncology ·Carlton L. Schwab, Diana P. English, Dana M. Roque, Stefania Bellone, Salvatore Lopez, Emiliano Cocco, Roberta Nicoletti, Thomas Rutherford, Peter E. Schwartz, Alessandro D. Santin	27
13	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer 2012 ·Journal of Clinical Oncology ·Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos, Duk‐Soo Bae, I Rzepka-Górska, Mariusz Bidziński, Giovanni Scambia, Svend Aage Engelholm, Florence Joly, Dirk Weber, Mona El-Hashimy, Jingjin Li, Farida Souami, (unknown), Silke Engelholm, Aristotelis Bamias, Peter E. Schwartz	95
14	HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas 2012 ·International Journal of Gynecological Pathology ·Federica Guzzo, Stefania Bellone, Natália Buza, Pei Hui, Luisa Carrara, Joyce Varughese, Emiliano Cocco, Marta Betti, Paola Todeschini, Sara Gasparrini, Peter E. Schwartz, Thomas Rutherford, Roberto Angioli, Sërgio Pecorelli, Alessandro D. Santin	33
15	HER-2/NEU overexpression in vulvar Paget disease: the Yale experience 2010 ·Journal of Clinical Pathology ·C. Richter, Pei Hui, Natália Buza, Dan‐Arin Silasi, Masoud Azodi, Alessandro D. Santin, Peter E. Schwartz, Thomas Rutherford	40
16	Diagnostic Markers for Early Detection of Ovarian Cancer 2008 ·Clinical Cancer Research ·Irene Visintin, Ziding Feng, Gary Longton, David C. Ward, Ayesha B. Alvero, Yinglei Lai, Jeannette L. Tenthorey, Aliza Leiser, (unknown), Herbert Yu, (unknown), Thomas Rutherford, Peter E. Schwartz, Gil Mor	307
17	Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. 2002 ·PubMed ·Seung Myung Dong, Sara I. Pai, Seo-Hee Rha, Allan Hildesheim, Robert J. Kurman, Peter E. Schwartz, Rodrigue Mortel, Larry McGowan, Mitchell Greenberg, Willard A. Barnes, David Sidransky	92
18	The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. 2001 ·PubMed ·Xiaohua Peng, Jong-Ho Won, Thomas Rutherford, Tomohiro Fujii, Daniel Zelterman, (unknown), (unknown), John Leavitt, Barry M. Kacinski, Ronald G. Crystal, Peter E. Schwartz, A. B. Deisseroth	50
19	Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. 1996 ·PubMed ·Setsuko K. Chambers, Carol A. Davis, Peter E. Schwartz, Ernest I. Kohorn, Joseph T. Chambers	8
20	Adenoid Basal Cell Carcinoma of the Vulva 1982 ·International Journal of Gynecological Pathology ·Maria J. Merino, Virginia A. LiVolsi, Peter E. Schwartz, Jerzy Rudnicki	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact